BCG Therapy in Superficial Bladder Tumours - Complications and Precautions

Steg, A; Adjiman, S; Debré, B

doi:10.1159/000474920

Cited by 37 publications

(15 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some authors recommend screening for abdominal aneurysms before starting treatment with intravesical BCG-immunotherapy 11. Our patient was not screened for aneurysms, therefore it is unknown whether or not an aneurysm was already present at the time of the BCG-installation.…”

Section: Discussionmentioning

confidence: 94%

Combined infection of vertebroplasty and aortic graft after intravesical BCG treatment

Santbergen¹,

Vriens

Lange

et al. 2013

BMJ Case Reports

View full text Add to dashboard Cite

We report a 58-year-old man with spondylodiscitis by Mycobacterium bovis-BCG 3 years after intravesical BCG treatment, and shortly after a vertebroplasty. Further examination showed a psoas abscess and oedema around an endovascular aortic graft, which had been placed 1 year earlier. Puncture of the psoas abscess also grew M bovis-BCG. The patient recovered with a combination of antituberculous treatment and surgery. With hindsight a mycotic aneurysm had been present at the time of aortic graft placement and spondylodiscitis at the time of vertebroplasty. This case shows that low grade and longstanding infections may occur following intravesical BCG installation.

show abstract

Section: Discussionmentioning

confidence: 94%

Combined infection of vertebroplasty and aortic graft after intravesical BCG treatment

Santbergen¹,

Vriens

Lange

et al. 2013

BMJ Case Reports

View full text Add to dashboard Cite

show abstract

“…Actual BCG sepsis is a rare event and has been reported in only 0.4% of all cases. In addition, some of these cases have been fatal [7,8]. Thus, the reported side effects limit the clinical applicability and acceptance of this effective immunotherapy and underscore the need for alternative forms of treatment.…”

Section: Introductionmentioning

confidence: 99%

Immunodominant PstS1 antigen of mycobacterium tuberculosis is a potent biological response modifier for the treatment of bladder cancer

et al. 2004

View full text Add to dashboard Cite

show abstract

“…Lamm et al published a review of complications in 2602 patients treated with intravesicular BCG. The incidence of systemic BCG infection defined as pneumonitis or hepatitis was only 0.7% 5 6. However, in a more recent review of 256 patients treated with intravesicular BCG at a single centre, Asin et al 7 reported an incidence of systemic BCG infection of 4.3% 8.…”

Section: Discussionmentioning

confidence: 99%

Mycobacterium bovisprosthetic joint infection following intravesical instillation of BCG for bladder cancer

Patel

Elzweig

2019

BMJ Case Rep

View full text Add to dashboard Cite

A 91-year-old man with a history of intravesicular BCG therapy for recurrent bladder cancer and bilateral total hip arthroplasty (THA) presented with left hip pain. He was noted to have a fluid collection over the left lateral hip and hip X-ray showed loosening of the prosthetic hip stem indicative of a prosthetic joint infection (PJI). He subsequently underwent removal of the THA and insertion of an antibiotic spacer. He was discharged on intravenous ceftriaxone for presumed culture negative PJI. Intraoperative acid fast bacillus culture later grew Mycobacterium tuberculosis complex, which was then differentiated to M. bovis. The M. bovis infection was thought to be a complication of the patient’s prior BCG therapy. He was initially started on isoniazid, rifampin, pyrazinamide and ethambutol pending cultures and sensitivities; pyrazinamide was discontinued after M. bovis was isolated on culture and susceptibility data confirmed the expected inherent resistance of M. bovis to pyrazinamide. The patient underwent successful THA revision and remains symptom-free at 1 year.

show abstract

BCG Therapy in Superficial Bladder Tumours - Complications and Precautions

Cited by 37 publications

References 10 publications

Combined infection of vertebroplasty and aortic graft after intravesical BCG treatment

Combined infection of vertebroplasty and aortic graft after intravesical BCG treatment

Immunodominant PstS1 antigen of mycobacterium tuberculosis is a potent biological response modifier for the treatment of bladder cancer

Mycobacterium bovisprosthetic joint infection following intravesical instillation of BCG for bladder cancer

Contact Info

Product

Resources

About